STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments.

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• The cGAS STING pathway is a key component of the innate immune response.
• Dysregulation of this pathway is linked to type I interferonopathies and other diseases like cardiac failure.
• Genetic mutations activating STING or affecting cGAS drive rare autoinflammatory conditions.

Purpose of the Study:

• To review potential therapeutic indications for modulating the cGAS STING pathway.
• To provide an overview of efforts in developing STING modulators (agonists and antagonists) for clinical research.
• To discuss the potential of these modulators as therapeutic drugs.

Main Methods:

• Literature review of preclinical and clinical data on the cGAS STING pathway.
• Analysis of current challenges and progress in developing small molecule STING modulators.
• Exploration of potential clinical applications and therapeutic strategies.

Main Results:

• While STING agonists have entered oncology trials, progress is slow, and developing selective antagonists is difficult.
• Novel low molecular weight compounds with potential therapeutic applications are emerging.
• No clinical data currently demonstrates therapeutic benefit from modulating the cGAS STING pathway.

Conclusions:

• Modulating the cGAS STING pathway holds therapeutic potential for various diseases beyond classical immune disorders.
• The development of clinically viable STING modulators is ongoing, with new compounds showing promise.
• Further research and clinical trials are needed to validate the therapeutic efficacy of cGAS STING pathway modulators.